Everything below concerns melanogenesis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-03. Numbers and descriptions here follow the published literature rather than marketing material.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved in the US, EU and Australia | Sale and import restricted; no licensed product |
| Typical test matrices | Urine, serum, seized powder | Urinary detection window is short |
| Primary identification method | LC-MS/MS against a reference standard | High-resolution mass used for confirmation |
| Data sources in the literature | Small trials, case reports, pharmacovigilance | No registrational trial dataset exists |
| Common marketing names | Melanotan 2, MT-II, MT-2 | Label content may not match declared peptide |
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
Regulatory treatment varies by jurisdiction and has changed over time. In several countries the peptide is handled as an unapproved prescription medicine, and import or sale for human use is restricted, while elsewhere it falls under poisons or controlled-substance schedules. Enforcement activity against online vendors has been reported in Australia, New Zealand, the United Kingdom and the United States. Scholarly writing discusses melanotan-2 chiefly as an experimental tool and as a case study in unregulated peptide supply, and its precise legal position in any given country should be checked against current national schedules.
Lyophilised melanotan-2 is comparatively robust when kept dry, cold and dark, and a desiccated powder stored at minus twenty degrees Celsius or below is generally expected to retain its chemical integrity for extended periods. In solution the peptide is far less stable, with degradation proceeding through oxidation of tryptophan and histidine residues, hydrolysis adjacent to the lactam bridge, and aggregation at higher concentrations. Repeated freeze-thaw cycling accelerates loss of the parent peak. Working aliquots are therefore prepared once, held cold, and used without letting the stock return to ambient temperature.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
The collection grew slowly and suffered another major fire in 1851, which destroyed two-thirds of Jefferson's original books. The Library of Congress faced space shortages, understaffing, and lack of funding, until the American Civil War increased the importance of legislative research to meet the demands of a growing federal government. In 1870, the library gained the right to receive two copies of every copyrightable work printed in the United States; it also built its collections through acquisitions and donations. Between 1890 and 1897, a new library building, now the Thomas Jefferson Building, was constructed. Two additional buildings, the John Adams Building (opened in 1939) and the James Madison Memorial Building (opened in 1980), were later added. The LC's Congressional Research Service provides objective non-partisan research to Congress to assist it in passing legislation. The library is open to the public for research, although only members of Congress, their staff, and library employees may borrow materials for use outside the library.
=== Mortality === RA reduces lifespan on average from three to twelve years. Young age at onset, long disease duration, the presence of other health problems, and characteristics of severe RA – such as poor functional ability or overall health status, a lot of joint damage on x-rays, the need for hospitalisation or involvement of organs other than the joints – have been shown to associate with higher mortality. Positive responses to treatment may indicate a better prognosis. A 2005 study by the Mayo Clinic noted that individuals with RA have a doubled risk of heart disease, independent of other risk factors such as diabetes, excessive alcohol use, and elevated cholesterol, blood pressure and body mass index. The mechanism by which RA causes this increased risk remains unknown; the presence of chronic inflammation has been proposed as a contributing factor. It is possible that the use of new biologic drug therapies extend the lifespan of people with RA and reduce the risk and progression of atherosclerosis. This is based on cohort and registry studies, and remains hypothetical. It is uncertain whether biologics improve vascular function in RA. There was an increase in total cholesterol and HDLc levels, and no improvement in the atherogenic index.
Ultrasound-assisted extractive electrospray ionization mass spectrometry (EESI-MS) has been developed at ETH Zurich (Switzerland) by Zhu, Chingin et al., (2008) for a rapid detection of melamine in untreated food samples. Ultrasounds are used to nebulize the melamine-containing liquids into a fine spray. The spray is then ionised by extractive electrospray ionisation (EESI) and analysed using tandem mass spectrometry (MS/MS). An analysis requires 30 seconds per sample. The limit of detection of melamine is a few nanograms of melamine per gram of milk. Huang et al. (2008) have also developed at Purdue University (US) a simpler instrumentation and a faster method by using a low-temperature plasma probe to ionize the samples. The major obstacles being solved, the ESI-MS technique allows now high-throughput analysis of melamine traces in complex mixtures. The Melaminometer was a hypothetical design for a synthetic biology circuit, to be used for detecting melamine and related chemical analogues such as cyanuric acid. The conceptual project is hosted at OpenWetWare as open source biology in collaboration with DIYbio and has been discussed in various newspapers in the context of homebrew biotechnology. As of October 2009, the design has not been verified. Because melamine resin is often used in food packaging and tableware, melamine at ppm level (1 part per million) in food and beverage has been reported due to migration from melamine-containing resins.
Sources: en.wikipedia.org
== Biography == In 1964 Bernd Michael Rode graduated from high school (“Akademisches Gymnasium Innsbruck”) and commenced studies in chemistry at the University of Innsbruck. In 1973 he received his Ph.D. degree in chemistry with sub auspiciis praesidentis from the University of Innsbruck. In 1973 Prof. Rode started his career as an assistant professor at the Institute of Inorganic and Analytical Chemistry of the University of Innsbruck. After research stays in Germany (University of Stuttgart and University of Karlsruhe) he became an associate professor in Innsbruck in the year 1976. After spending a 1-year research stay at the University of Tokyo, Prof. Rode started his professorship at the Institute of Inorganic and Theoretical Chemistry at the University of Innsbruck. From 2006 to 2011 he was head of the Department of Theoretical Chemistry and head of the Institute for General Inorganic and Theoretical Chemistry. One of Prof. Rode’s largest achievements was the foundation of the University Network ASEA-UNINET (Austrian South East Asian University Partnership Network) in 1994. The foundations for this network were laid by informal contacts between the University of Innsbruck and Thai Universities that date back to the 1970s. In the 1980s partnerships between the University of Innsbruck, the University of Vienna, the University of Agricultural Sciences Vienna, the Chulalongkorn University, the Mahidol University, the Kasetsart University and the Chiang Mai University were concluded.
Heparin was discovered by Jay McLean and William Henry Howell in 1916, it was first isolated from a canine liver, which in Greek translates to hepar. Heparin targets multiple factors in the blood coagulation cascade, one of them being FXa. At first, it had many side effects but for the next twenty years, investigators worked on heparin to make it better and safer. It entered clinical trials in 1935 and the first drug was launched in 1936. Chains of natural heparin can vary from 5.000 to 40.000 daltons. In the 1980s Low molecular weight heparin (LMWH) were developed and they only contain chains with an average molecular weight of less than 8.000 Da.
The protein this gene encodes for is often called Sep15 however in the case of mice, it is named SelM. This protein is a selenoprotein only found in eukaryotes. This domain has a thioredoxin-like domain and a surface accessible active site redox motif. This suggests that they function as thiol-disulfide isomerases involved in disulfide bond formation in the endoplasmic reticulum.
reactivity The tendency of a particular chemical substance to undergo a chemical reaction, either by itself or with other substances, generally referring to either or both of two distinct observations: whether or not a substance reacts under a specific set of circumstances, and how quickly it reacts (i.e. the reaction rate). Thermodynamically, a chemical reaction occurs because the products (taken as a group) exist at a lower free energy than the reactants, and hence are more energetically "stable", but the concept of reactivity may also embody kinetic factors, depending on the usage. Chemical stability and chemical compatibility are related but distinct concepts.
Sources: en.wikipedia.org
== Patents == US patent 3987302, George S. Hurst, Marvin G. Payne, Edward B. Wagner, "Resonance ionization for analytical spectroscopy", issued October 19, 1976 US patent 4,442,354, Hurst, G. Samuel, James E. Parks, James E. & Schmitt, Harold W, "Method of analyzing for a component in a sample", issued April 10, 1984
{\displaystyle {\frac {d}{dt}}{\begin{pmatrix}n_{E}\\n_{I}\end{pmatrix}}={\begin{pmatrix}-1/\tau _{E}&R_{0}/\tau _{I}\\1/\tau _{E}&-1/\tau _{I}\end{pmatrix}}{\begin{pmatrix}n_{E}\\n_{I}\end{pmatrix}}.}
== Medical training and career == Though born in Oklahoma City, Wilson grew up in Whittier, California. He completed his undergraduate degree in biology from California State University, Fullerton in 1974 and a master's degree in molecular biology and biochemistry from University of California, Irvine in 1977. He received his doctor of medicine degree from University of California, San Diego in 1984. The early part of his career saw him completing residency at the Mayo Clinic and taking professor and research roles at various universities. He served as a professor and Chair of the Department of Ophthalmology at the University of Washington in Seattle from 1998 to 2003, and was named Grace E. Hill Endowed Chair in Vision Research. Since 2003, he has been professor of ophthalmology and staff cornea and refractive surgeon at the Cleveland Clinic in Ohio, and he has served as the cornea and refractive fellowship director there 2006-2017. Wilson is the inventor of topical losartan treatment for corneal scarring/fibrosis. Wilson's laboratory studying corneal wound healing was funded by the National Eye Institute and the U.S. Department of Defense from 1993 to 2025.
The staple commodities regularly contaminated with aflatoxins include cassava, chilies, corn, cottonseed, millet, peanuts, rice, sorghum, sunflower seeds, tree nuts, wheat, and a variety of spices intended for human or animal consumption. Aflatoxins have been isolated from all major cereal crops, and sources as diverse as peanut butter and cannabis. Aflatoxin transformation products are sometimes found in eggs, milk products, and meat when animals are fed contaminated grains. Aflatoxins are produced by both Aspergillus flavus and Aspergillus parasiticus, which are common forms of "weedy" molds widespread in nature. Aflatoxins occur also in Aspergillus pseudocaelatus, Aspergillus nomius and Aspergillus pseudonomius. The presence of these molds does not always indicate that harmful levels of aflatoxin are present, but it does indicate a significant risk. The molds can colonize and contaminate food before harvest or during storage, especially following prolonged exposure to a high-humidity environment or to stressful conditions such as drought. Aflatoxin contamination is increasing in crops such as maize as a result of climate change. The native habitat of Aspergillus is in soil, decaying vegetation, hay, and grains undergoing microbiological deterioration, but it invades all types of organic substrates whenever conditions are favorable for its growth. Favorable conditions for production of aflatoxins include high moisture content (at least 7%) and temperatures from 55 to 104 °F (13 to 40 °C), where the optimum is 27 to 30 °C (81 to 86 °F).
=== Chemical === One of the first historical QSPR applications (as pre-condition to QSAR) was to predict boiling points. It is well known for instance that within a particular family of chemical compounds, especially of organic chemistry, that there are strong correlations between structure and observed properties. A simple example is the relationship between the number of carbons in alkanes and their boiling points. There is a clear trend in the increase of boiling point with an increase in the number carbons, and this serves as a means for predicting the boiling points of higher alkanes. A still very interesting application is the Hammett equation, Taft equation and pKa prediction methods.
Sources: en.wikipedia.org
Regulatory treatment varies by country. In the United States, the European Union and Australia it is an unapproved drug and its sale is restricted, while some other jurisdictions list it as prescription-only or controlled. The applicable rules depend on the country of import.
Reversed-phase LC-MS/MS is the usual approach for both identification and quantitation. High-resolution mass spectrometry and peptide mapping serve as confirmatory methods. Immunoassays are rarely used alone because of cross-reactivity.
Published testing of seized and purchased samples frequently reports discrepancies between declared and measured peptide content. Counter-ion content and residual solvents add further variation. Independent analysis is the only way to confirm composition.
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.